GCN2 also protects haematopoietic cancer cells from deleterious effects of asparaginase treatment and proteasome inhibition, two commonly used anti-cancer therapies that trigger intracellular amino acid depletion (Suraweera et al, 2012; Nakamura et al, 2018; Saavedra-García et al, 2021). This evidence concerns the gene EIF2AK4 and cancer.